“The addition of this assay allows researchers in oncology and development insight into potential interactions with this receptor in the earliest stages of their research.”

STATE COLLEGE, Pa. (PRWEB)
May 17, 2022

INDIGO Biosciences, the recognized industry leader in nuclear receptor reporter assays, announced today the expanding of their robust preclinical testing portfolio of cell-based reporter assays to include the Human Estrogen-related Receptor Beta (NR3B2; ERRβ). This cell-based in vitro reporter assay provides researchers with the ability to quickly make critical decisions about potential drug candidates before moving into clinical trials.

“We are excited to add the Estrogen-related Receptor Beta to our portfolio to allow researchers to better understand how a potential drug effects ERRβ activity.” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “The addition of this assay allows researchers in oncology and development insight into potential interactions with this receptor in the earliest stages of their research.”

Like it’s other two family members, estrogen-related receptor alpha and estrogen-related receptor gamma, ERRβ is considered an orphan receptor because no natural ligand has been found that binds to ERRβ. ERRβ is a key pluripotency regulator and plays a role in inner ear development, and retinal development. A growing number of studies also suggest that ERRβ plays a role in tumor suppression for certain types of cancer including prostate, uterine, breast, and glioblastoma. This presents ERRβ as a potentially important therapeutic target for combating these diseases.

INDIGO’s in vitro estrogen-related receptor beta assay kit is all-inclusive containing everything needed to perform the assay including live cells. In vitro assays, such as those offered by INDIGO, provide important early indications of a compound or antibody’s potential for progressing to further development and clinical testing. INDIGO’s assays allow researchers to definitively determine what receptors are affected to ensure the selectivity of target compounds, a key piece of information necessary to proceed with development. The new ERRβ reporter assay is available both as a screening service or as an all-inclusive kit.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at indigobiosciences.com/.

Share article on social media or email: